Advertisement

Topics

Glycyx gets rights to Valeant's methylnaltrexone bromide for oncology indications

15:40 EDT 28 Jun 2017 | Elsevier Business Intelligence

Valeant Pharmaceuticals International Inc. licensed Glycyx PharmaVentures Ltd. exclusive rights to develop and commercialize ...

Original Article: Glycyx gets rights to Valeant's methylnaltrexone bromide for oncology indications

NEXT ARTICLE

More From BioPortfolio on "Glycyx gets rights to Valeant's methylnaltrexone bromide for oncology indications"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...